Clascoterone, a topical androgen receptor inhibitor already approved for acne, shows promise for treating pattern baldness by blocking the effects of dihydrotestosterone (DHT) at the hair follicle level. Unlike minoxidil, which increases blood flow, clascoterone targets the hormonal root cause of hair loss. This localized action aims to interrupt follicle miniaturization with minimal systemic hormonal effects, offering a new approach to androgenetic alopecia.